Le Lézard
Classified in: Health
Subjects: PER, BFA

Peter Cashion Joins The Pancreatic Cancer Action Network Board Of Directors


MANHATTAN BEACH, Calif., Dec. 12, 2017 /PRNewswire-USNewswire/ -- The Pancreatic Cancer Action Network (PanCAN) is proud to announce that Peter Cashion, MBA, has been elected to its Board of Directors. In his new leadership role in the fight against the world's toughest cancer, Cashion brings over 20 years' experience with the International Finance Corporation as a chief investment officer and equity head.

Cashion's late wife, Andra Tamburro, was diagnosed with pancreatic cancer in January 2013 and died from the disease in September of that same year. Cashion resides in Washington, D.C., where he lives with his two sons. He has been an avid volunteer and fundraiser for PurpleStride, the walk to end pancreatic cancer, serving as a team captain. Over the last five years Cashion has raised more than $180,000.

"My hope in joining the PanCAN Board of Directors is to ensure that no one has to experience the loss that my family and I did," said Cashion. "I want to use my voice so that people can see that we can fight back against this disease in a positive and productive way."

Cashion received his bachelor's degree from the University of Western Ontario and received his Master of Business Administration (MBA) from Queens University, also in Canada.  

"Peter's leadership and professional experience, coupled with his passion to fight this disease, bring tremendous value to our Board of Directors," said Julie Fleshman, JD, MBA, president and CEO of PanCAN. "Peter's expertise strengthens our organization, and we couldn't be more pleased to welcome him into this role."

The Pancreatic Cancer Action Network has an urgent goal to improve outcomes for patients battling the disease today and double survival by 2020. This work is supported by critical initiatives, including Precision PromiseSM, Know Your Tumor® and the Patient Registry.

Support the Pancreatic Cancer Action Network's urgent goal to double survival by 2020. Follow the Pancreatic Cancer Action Network on Twitter, Instagram and Facebook.

About the Pancreatic Cancer Action Network
The Pancreatic Cancer Action Network (PanCAN) is dedicated to fighting the world's toughest cancer. In our urgent mission to save lives, we attack pancreatic cancer on all fronts: research, clinical initiatives, patient services and advocacy. Our effort is amplified by a nationwide network of grassroots support. We are determined to improve patient outcomes today and to double survival by 2020.

Media Contact:
Andrew McLean              
Media Relations Specialist
Pancreatic Cancer Action Network
Direct: 310-706-3357, ext. 3516
Email: [email protected]

The Pancreatic Cancer Action Network (PanCAN) is dedicated to fighting the world's toughest cancer. In our urgent mission to save lives, we attack pancreatic cancer on all fronts: research, clinical initiatives, patient services and advocacy. Our effort is amplified by a nationwide network of grassroots support. We are determined to improve outcomes today and to double survival by 2020. (PRNewsfoto/Pancreatic Cancer Action Network)

SOURCE Pancreatic Cancer Action Network


These press releases may also interest you

at 10:05
Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced two presentations, including an oral presentation on the Phase 1 first-in-human study of OBX-115, a novel engineered...

at 10:05
Nuvation Bio Inc. , a late-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that updated data from the Phase 2 TRUST-I...

at 10:05
AffyImmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, today announced an abstract detailing its affinity-tuned CAR T therapy AIC100 will be presented at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, held...

at 10:05
SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group, today announced it will present a Trial-in-Progress poster on the DUET-01 Phase 1/2 study of BOXR1030 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting...

at 10:05
After more than 60 years of researching the power of plants in Germany, Bayer Consumer Health is introducing Iberogasttm, a plant-based digestive relief product, to the United States. Formulated with a clinically proven, proprietary six-herb blend,...

at 10:05
Agenus Inc. ("Agenus") , a leader in developing novel immunological agents to treat various cancers, today announced an upcoming presentation from the Phase 1b trial of botensilimab in combination with balstilimab ("BOT/BAL") in patients with...



News published on and distributed by: